NEUREN PHARMACEUTICALS LIMITED — Director's Dealing 2011

Oct 25, 2011

Appendix 3Y Change of Director’s Interest Notice

Rule 3.19A.2

Appendix 3Y

Change of Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity:	Neuren Pharmaceuticals Limited
ARBN:	111 496 130

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Dr Robin Lance Congreve
Date of last notice	30 September 2008

Part 1 - Change of director’s relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

	Direct or indirect interest	Direct or indirect interest	Direct interest
	Nature of indirect interest(including registered holder)Note: Provide details of the circumstances giving rise to the relevantinterest.
	Date of change		26 October 2011.
	No. of securities held prior to change		22,386,224 Ordinary Shares.
	Class		Unlisted options over Ordinary Shares with an exerciseprice of A$0.0377per option.
	Number acquired		20,000,000 unlisted options under the Share OptionPlan as approved byshareholders.
	Number disposed		Nil
	Value/ConsiderationNote: If consideration is non-cash, provide details and estimated valuation		Nil
	No of securities held after chane		22,386,224 Ordinary Shares and 20,000,000 unlistedoptions with an exercise price of A$0.0377 per option.
	. g

• See chapter 19 for defined terms.

01/01/2011 Appendix 3Y Page 1

Appendix 3Y Change of Director’s Interest Notice

Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back

Issue of unlisted options under the Share Option Plan on the terms approved by shareholders.

Part 2 – Change of director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract	Not applicable
Nature of interest	Not applicable
Name of registered holder(if issued securities)	Not applicable
Date of change	Not applicable
No. and class of securities to whichinterest related prior to changeNote: Details are only required for a contract in relationto which the interest has changed	Not applicable
Interest acquired	Not applicable
Interest disposed	Not applicable
Value/ConsiderationNote: If consideration is non-cash, provide details and anestimated valuation	Not applicable
Interest after change	Not applicable

Part 3 –[+] Closed period

Part 3 –+Closed period
Were the interests in the securities or contracts detailedabove traded during a+closed period where prior writtenclearance was required?	No, unlisted options are excluded fromthe Company’s Securities TradingPolicy.
If so, was prior written clearance provided to allow the tradeto proceed during this period?	Not applicable
If prior written clearance was provided, on what date was thisprovided?	Not applicable

• See chapter 19 for defined terms.

Appendix 3Y Page 2

01/01/2011